Treatment with obinutuzumab-chlorambucil , as compared with rituximab-chlorambucil , resulted in prolongation of progression-free survival ( hazard ratio , 0.39 ; 95 % CI , 0.31 to 0.49 ; P < 0.001 ) and higher rates of complete response ( 20.7 % vs. 7.0 % ) and molecular response .